Heart

Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy

Positive interim results prompt request for meeting with FDA SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced today that interim results ofits phase II/III trial comparing CPOP-R, in which pixantrone issubstituted for doxorubicin in standard CHOP-R first-line treatmentof patients with aggressive non-Hodgkin's lymphoma (NHL), resultedin essentially al...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's GeneticResearch - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today reported results frompreclinical research demonstrating that antibodies directed to apotential new target, angiopoietin-like protein 4 (ANGPTL4),rapidly lower triglycerides and cholesterol. Research suggests thata mon...

Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for Heart Failure

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 19, 2007 - GeronCorporation (Nasdaq: GERN) today reported that research documentingthe scalable production, survival following engraftment andpositive impact on cardiac function in infarcted rats was presentedtoday for GRNCM1, the company's human embryonic stem cell(hESC)-based therapeutic for heart failure, at the InternationalSociety for Stem Cell...

Treating Heart Disease Risk Factors May Slow Alzheimer's Disease Progression

- Late Life Weight Loss and "Motivational Reserve" May Also AffectAlzheimer's Risk - WASHINGTON, June 10, 2007 /PRNewswire-USNewswire/ -- A new studysuggests that treating risk factors for heart disease and stroke,such as high blood pressure and diabetes, may slow the progressionof Alzheimer's disease, according to research reported today at the2nd Alzheimer's Association International Co...

Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007

HAMBURG, Germany, June 11, 2007 /PRNewswire/ -- NovaCardia, Inc.today presented preliminary results from a pilot Phase 3 trial ofKW-3902, an adenosine A1 receptor antagonist in development for thetreatment of patients with acute congestive heart failure (CHF),that indicate a strong trend toward efficacy for the 30 milligramdose. Patients treated with KW-3902 experienced a higher rate ofi...

Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication

CHICAGO, May 1, 2007—The drug levosimendan did not improvesurvival for patients with decompensated heart failure whencompared with a more widely-used treatment for this condition,dobutamine, according to a study in the May 2 issue of Acute decompensated heart failure (ADHF; severe heart failurecharacterized by inability of the heart to maintain adequate bloodci...

deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack

REYKJAVIK, Iceland, May 01, 2007 /PRNewswire-FirstCall/ --deCODE genetics today announced positive top-line results from itsPhase I multiple dose clinical trial of DG051, which the company isdeveloping for the prevention of heart attack. In the study, arandomized, double-blind, multi- dose, ascending dose,placebo-controlled clinical trial, a total of 40 healthy subjectswere exposed to DG...

Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study

<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: left; tab-stops: 0in"align="left"> <li style="MARGIN: 0in 0in 0pt; tab-stops: list .5in; mso-list: l1 level1 lfo2"> <span style="FONT-SIZE: 11pt; FONT-FAMILY: 'News Gothic MT'; mso-bidi-font-weight: bold">Independent Japanese study demonstrates dramati...

Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study

Independent Japanese study demonstrates dramaticbenefits of adding Diovan to conventional therapy Study halted early due to superior outcomes forDiovan patients BASEL,Switzerland, April 27, 2007 - New findings from th...

First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan

Unprecedented Evidence for the Effectiveness of HypertensionTreatment Valsartan in Preventing Cardiovascular Events in JapanesePatients TOKYO, April 26, 2007 /Xinhua-PRNewswire/ -- The clinicaloutcomes of the JIKEI HEART Study, the large-scale clinical trialheaded by the Jikei University School of Medicine, was todaypublished in the internationally renowned medical journal TheLancet. The...

New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting

ADDISON, Texas, April 19, 2007 /PRNewswire/ -- New clinicaltrial results for heart transplant patients will be released at theupcoming International Society for Heart and Lung Transplantation(ISHLT) 27th Annual Meeting and Scientific Sessions at the HiltonSan Francisco, April 25-28, 2007. Results show promise for efficacyand safety of immunosuppression therapy and lower incidences ofacut...

New Cardioprotective Drug Could Provide Boost For Post-Bypass Surgery Heart Health

SOMERSET, N.J., April 5, 2007-- Stent thrombosis,restenosis and lifelong prescriptions. Millions of patients havediscovered that the drug-coated stents used as part of their heartoperations may be having more of a detrimental effect on theirhealth than medical experts have ever publicly acknowledged. Recentarticles in medical journals suggest that unless patients whoreceive drug-eluting...

New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy

COLLEGEVILLE, Pa., April 03, 2007 /PRNewswire-FirstCall/ --Wyeth Pharmaceuticals, a division of Wyeth , provides comment on are- analysis of pooled data from both hormone therapy arms of theWomen's Health Initiative (WHI) Study published today in theJournal of the American Medical Association. The pooled analysisshowed no apparent increase in coronary heart disease for women whoinitiate...

Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show

NEW ORLEANS--(BUSINESS WIRE)--Mar 27, 2007 - Pfizer announced todaythat Lipitor(R) (atorvastatin calcium) Tablets (80 mg) loweredhospitalization costs by significantly reducing the risk ofcardiovascular events in patients with heart disease, according totwo separate economic analyses. The data were presented at theannual meeting of the American College of Cardiology. "One of these analyse...

Heart Attack Patients Treated With Novel Stem Cell Therapy Experience Significant Improvement in Heart and Lung Function

CHICAGO, March 27, 2007--Heart attack patients who received annew intravenous adult stem cell therapy, Provacel™,experienced a lower number of adverse events, such as cardiacarrhythmias, and had significant improvements in heart, lung andglobal function compared to those who received a placebo, accordingto six-month P...

Calcium Plaque Build-up in the Arteries Leads to Coronary Heart Disease in Multi-Ethnic Groups

BETHESDA, Md., March 26, 2007--Having a build-up of calciumplaque in the arteries means increased risk of heart attacks anddeath from heart disease in multiple ethnic groups, according tonew findings from the Multi-Ethnic Study of Atherosclerosis (MESA)funded by the National Heart, Lung, and Blood Institute of theNational Institutes of Health. Previous studies have shown thatincreased co...

Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2 Predicts Heart Disease Risk in Metabolic Syndrome Patients

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Study results showthat elevated lipoprotein-associated phospholipase A2 (Lp-PLA2), acardiovascular-specific inflammatory enzyme associated withunstable plaque that can lead to heart attack and stroke, isespecially predictive of heart disease risk in patients with themetabolic syndrome--a serious medical condition that affects nearly50 million Ame...

BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality

JERUSALEM--(BUSINESS WIRE)--Mar 7, 2007 - BioLineRx Ltd.(TASE:BLRX), Israel's leading drug development company, reportedtoday pre-clinical data from trials of BL-1040 demonstrating thatBL-1040 is effective in preventing deterioration of the myocardiumafter a myocardial infarction (MI), thereby reducing left ventricledilatation and eventual heart failure in a pig model. ProfessorJonathan Leo...

DVT Awareness Survey Findings: Heart and Respiratory Patients

WASHINGTON, March 06, 2007 /PRNewswire/ -- Up to two millionAmericans are affected each year by DVT, with up to 600,000hospitalized. Its primary complication, pulmonary embolism (PE),claims up to 300,000 lives annually -- more than breast cancer andAIDS combined. People who suffer from cardiovascular disease may beat increased risk for DVT, because these factors also heighten thelikeliho...